Skip to main content
Premium Trial:

Request an Annual Quote

George Poste, Brian Ward, Stella Quan

Premium
George Poste is taking on the role of non-executive vice chairman and chief scientific advisor of CDX Holdings, the parent company of Caris Diagnostics and Caris Molecular Diagnostics. Poste also has been named non-executive chairman of Caris Molecular Diagnostics. He has been a director of Caris Diagnostics since November 2006.
 
Poste is chief scientist of the Complex Adaptive Systems Initiative and director of The Biodesign Institute at Arizona State University. He also is CEO of Health Technology Networks. Between 1992 and 1999, Poste was chief science and technology officer and president of R&D at SmithKline Beecham, prior to its merger with Glaxo Wellcome.
 

 
The DNA Repair Company has appointed Brian Ward to be executive VP and it has named Stella Quan to be senior director of product development. Ward formerly was senior VP for Genomic Health. He also has served as president of medical genetic services and senior vice president of operations at Myriad Genetic Laboratories, and he has worked at Genzyme Genetics and at the University of Colorado.
 
Quan was director of immunoassay development for BioMérieux, was senior director of operations at Tripath Oncology, and she was involved in research and development at Chiron.

Filed under

The Scan

Expanded Genetic Testing Uncovers Hereditary Cancer Risk in Significant Subset of Cancer Patients

In Genome Medicine, researchers found pathogenic or likely pathogenic hereditary cancer risk variants in close to 17 percent of the 17,523 patients profiled with expanded germline genetic testing.

Mitochondrial Replacement Therapy Embryos Appear Largely Normal in Single-Cell 'Omics Analyses

Embryos produced with spindle transfer-based mitochondrial replacement had delayed demethylation, but typical aneuploidy and transcriptome features in a PLOS Biology study.

Cancer Patients Report Quality of Life Benefits for Immune Checkpoint Inhibitors

Immune checkpoint inhibitor immunotherapy was linked in JAMA Network Open to enhanced quality of life compared to other treatment types in cancer patients.

Researchers Compare WGS, Exome Sequencing-Based Mendelian Disease Diagnosis

Investigators find a diagnostic edge for whole-genome sequencing, while highlighting the cost advantages and improving diagnostic rate of exome sequencing in EJHG.